# FDA recall D-0742-2022

> **Vitae Enim Vitae Scientific, Inc.** · Class II · drug recall initiated 2022-03-14.

## Product

PAPAVERINE HYDROCHLORIDE Injection, USP, 60 mg/2mL (30 mg/mL), packaged as a) 25 x 2mL Single Use Vials per box (NDC 72516-024-25) and b) 10 x 2mL Single Use Vials per box (NDC 72516-024-10); Manufactured for Oryza Pharmaceuticals, Inc.

## Reason for recall

Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the sterility of products intended to be sterile.

## Distribution

Nationwide in the U.S.A

## Key facts

- **Recall number:** D-0742-2022
- **Recalling firm:** Vitae Enim Vitae Scientific, Inc.
- **Classification:** Class II
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2022-03-14
- **Report date:** 2022-04-13
- **Termination date:** 2024-08-15

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** San Diego, CA, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0742-2022

## Citation

> AI Analytics. FDA recall D-0742-2022. Retrieved 2026-06-03 from https://api.ai-analytics.org/recall/D-0742-2022. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*